Exchange: NASDAQ·Updated 04:15 PM EDT
News
all
press releases
STRO Stock Plummets 15% — What Drove The Selloff?
H.C. Wainwright believes the selloff largely reflects an overreaction to the limited efficacy details disclosed for STRO-004 by the company.
Stocktwits
More News
Why is Sutro Biopharma Stock Falling On Wednesday?
Sutro Biopharma stock falls after its STRO-004 Phase 1 update, with DLTs reported at the highest dose and the next update planned for 2027.read more...
Benzinga
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
Upstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +6.41% and +15.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates
BioAge Labs, Inc. (BIOA) delivered earnings and revenue surprises of +10.77% and +172.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Gemini Space Posts Upbeat Q1 Results, Joins Figma, Sutro Biopharma And Other Big Stocks Moving Higher On Friday
Dow Jones falls 400 points, while Gemini Space Station Inc (NASDAQ: GEMI) sees 25.7% jump after strong financial results and $100M investment.read more...
Benzinga
MannKind (MNKD) Reports Q1 Loss, Misses Revenue Estimates
MannKind (MNKD) delivered earnings and revenue surprises of -150.00% and -13.05%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Sutro Biopharma (NASDAQ:STRO) Stock Rating Upgraded by Truist Financial
Truist Financial raised shares of Sutro Biopharma to a "strong-buy" rating in a research report on Monday...
MarketBeat
Sutro Biopharma (NASDAQ:STRO) Sets New 1-Year High - Still a Buy?
Sutro Biopharma (NASDAQ:STRO) Sets New 52-Week High - Still a Buy...
MarketBeat
Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates
Ocugen (OCGN) delivered earnings and revenue surprises of -12.57% and +27.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Sutro Biopharma (NASDAQ:STRO) Upgraded by Mizuho to "Strong-Buy" Rating
Mizuho upgraded shares of Sutro Biopharma to a "strong-buy" rating in a report on Thursday...
MarketBeat

Advertisement|Remove ads.